You are here

Home » Content

Erken Evre Meme Kanseri Nedeni ile Yapılan Meme Koruyucu Cerrahi Sonrası Nüks, Sağ Kalım ve Hasta Memnuniyetine Etki Eden Faktörler

THE FACTORS THAT EFFECT RECURRENCES, SURVIVAL AND SATISFACTION OF PATIENTS WITH EARLY STAGE BREAST CARCINOMA TREATED WITH BREAST CONSERVING THERAPY

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2006

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Objective: To demonstrate the demographic properties, local control and survival and contentment of therapy by patients with early breast cancer treated with breast conserving therapy. Methods: Between 1999 and 2005, twenty six patients' records were retrieved. Results: The average age of 26 patients was 51 (+/-8) years, of which 14 were premenopausal. The average follow up time was 30 (+/-21) months. Invasive ductal carcinoma was reported in 25 patients and while one patient had Tx, 17 had T1 and 8 had T2; 17 patients had N0, 4 N1, 4 N2; 2 had nuclear grade I, 15 II, 8 III. Eight patients had less than 1cm of clear margin. Fourteen of the patients had estrogen, whereas 13 had progesterone, and 7 had c erb b2 receptors. Seventeen patients received chemothera¬py, 21 had hormonotherapy. One patient died because of multi¬ple metastases. The mortality rate was 3.8% and no local recur¬rences were observed. Only 18.18% of patients were unsatisfied with therapy and 9.09% were unhappy with the new shape of their breast. Conclusion: Since the number of patients are few, we could not clarify the criteria that effect local and systemic recurrence and mortality. However, there was a positive correlation between the education level and satisfaction both with therapy (p=0.04) and the new shape of the breast (p=0.024).
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Meme koruyucu ameliyat yapılan erken evre meme kanserli hastaların demografik özelliklerini, lokal kontrolü ve yaşam süresini etkileyen faktörleri ve tedaviden memnuniyetlerini belirlemek. Yöntem: 1999 ile 2005 yılları arasında ameliyat edilen 26 hasta retrospektif olarak incelendi. Bulgular: Yaş ortalaması 51 (+/-8). Hastaların 14'ü premenopozal dönemdeydi. Ortalama takip süresi 30 (+/-21) aydır. Yirmi beş hastanın patoloji rapor sonucu invazif duktal karsinom; biri Tx, 17'si T1 ve 8'i T2'dir. Aksilla incelemelerini 17'si N0, 4'ü N1, 4'ü N2; nükleer gradları 2' sinin I, 15'inin II ve 8' inin III' tür. Bir hastanın bilgilerine ulaşılamamıştır. Sekiz hastada cerrahi sınır 1 cm'-den azdı. On yedi hastanın 14'ünde östrojen, 13'ünde progest-ron, 10 hastanın 7'sinde ise c erb b2 pozitifdi. Hastaların 17'si ke-moterapi, 21'i hormonoterapi aldı. Hastalarımızda ölüm oranı %3.80, lokal nüks 0 ve uzak metastaz %3.80' tür. Hastaların %18,18'i tedaviden, %9.09'u memenin şeklinden memnun olmadığını belirtti. Sonuç: Az sayıdaki hasta grubumuzda lokal ve sistemik rekürensi ve mortaliteyi etkileyen faktör tespit edilemedi. Eğitim durumları ile yapılan tedaviden (p=0.04) ve yeni meme şeklinden memnuniyet (p=0.024) arasında pozitif ilişki bulundu.
FULL TEXT (PDF): 
PDF icon arastrmx_116859_10_pp_160-164.pdf
  • 4
160-164
  • Turkish

REFERENCES

References: 

1. Fisher B, Anderson S, Bryant J ve ark. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347: 1233-41.
2. Luu H, Otis CN, Reed WP Jr, Garb JL, Frank JL. The unsatisfactory margin in breast cancer surgery. Am J Surg 1999; 178: 362-6.
3. Chung MA, Cady B. Breast cancer: surgical therapy. Current Surgical Therapy'de. Ed. Cameron H. 7. baskı. St. Louis, Mosby, 2001; 702-9.
4. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Eng J Med 1995; 333: 1444-5.
5. Van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong
D. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Nat Cancer Inst 2000; 92: 1143-50.
6. Recht A, Connolly JL, Schnitt SJ, Horris JR. The effect of young age on tumor recurrence in the treated breast after conservative surgery and radio¬therapy. Int J Radiat Oncol Biol Phy 1988; 1: 3-10.
7. Fowble BL, Schultz DJ, Overmoyer B, Solin LJ, Fox K, Jardines L, Orel S, Glick JH. The influence of young age on out come in early stage breast cancer. Int J Radiat Oncol Biol Phy 1994; 30: 23-33.
8. Borger J, Kemperman H, Hart A, Peterse H, van Dongen J, Bartelink H.
Risk factors in breast-conserving therapy. J Clin Oncol 1994; 12: 653-60.
9. Elkhuizen PH, van de Vijyer MJ, Hermans J, Zonderland HM, van de Velde CJ, Leer JW. Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phy 1998; 41: 801-7.
10. Voogd AC, Nielsen M, Peterse JL, Blichert-toft M ve ark. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large Europian randonized trials. J Clin Oncol 2001; 19: 1688-97.
11. Kim KJ, Huh SJ, Yang JH, Park W, Nam SJ, Kim JH. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy. Jpn J Clin Oncol 2005; 35: 126-33.
12. Oshumi S, Sakamoto G, Takashima S, Koyama H, Shin E, Suemasu K.
Long-term results of breast-conserving treatment of early-stage breast cancer in Japanese women from multi-center investigation. Jpn J Clin Oncol 2003;33(2):61-7.
13. Bartelink H, Horiot JC, Poortmans P ve ark. Recurrence rates after treat¬ment of breast cancer with standard radiothaerapy with or without additional radiation. N Engl J Med 2001; 345: 1378-87.
14. Barthelmes L, Awa AA, Crawford DJ. Effect of cavity margin shaving to ensure completeness of excision completeness of excision on local recurrence rates following breast conserving surgery. Eur J Surg Oncol 2003; 29: 644-8.

Thank you for copying data from http://www.arastirmax.com